A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of RO7434656, An Antisense Inhibitor Of Complement Factor B, In Patients With Primary IgA Nephropathy At High Risk Of Progression (IMAGINATION)

Principal Investigator

Dr Katherine Bull

Contact us

Email: renalandtransplanttrials@ouh.nhs.uk

IRAS number

1007821